The abstract is read at the publisher; the summary is JClub's.
A biomarker-supported metabolic endotype linked to insulin signaling, cellular bioenergetics, and lipid-lysosomal biology is proposed to span subsets of both Alzheimer’s and Parkinson’s disease.
- Why it matters: Mixed outcomes for metabolically targeted therapies may reflect trial designs that enroll biologically unselected participants and use endpoints distant from the targeted mechanism.
- What they did: The authors propose a modular four-tier framework combining prodromal risk, metabolic vulnerability, pathway-specific confirmation, and mechanistic deep phenotyping to enrich for the endotype.
- The result: Enriching for this metabolic endotype in all-comer trials could reduce signal dilution and make therapeutic effects more interpretable and mechanism-informative.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.